As shown in Table 2, there is no statistical difference in patients with a higher (≥12%) or lower (<12%) increase of anti-ENO1 Ab after surgery with regards to gender, histological subtypes, pTNM stages, tumor volumes, or EGFR mutation status. The gene discussed is EGFR; the disease is neoplasm.